Gray, C.M. et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162, 1780−1788

Department of Microbiology and Immunology, Stanford University, Stanford, California, United States
The Journal of Immunology (Impact Factor: 4.92). 03/1999; 162(3):1780-8.
Source: PubMed


Peptide/MHC tetrameric complexes were used to enumerate the frequency of HLA class I-restricted epitope-specific CD8+ T cells in 18 HLA-A*0201 HIV type 1-infected asymptomatic patients. HLA-A*0201 molecules were complexed to HIV Gag p17 (amino acids 77-85) and reverse transcriptase (amino acids 464-472) peptides, biotinylated, and bound to streptavidin-phycoerythrin to form tetramers. We show in this study that 17 of 18 HIV-1-infected asymptomatic patients have circulating frequencies of 1/50-1/1000 CD8+ T cells that recognize both Gag and Pol CTL epitopes or either epitope alone. The functional nature of these cells is open to interpretation, as we show that despite relatively high frequencies of fresh epitope-specific CD8+ T cells, variant epitope sequences in viral plasma progeny were rare. In addition, the majority of tetramer-positive cells did not display discernible fresh CTL activity; only after restimulation with specific peptide in culture was there an expansion of epitope-specific CD8+ cells, correlating with high CTL activity. These data suggest that fresh tetramer-stained cells probably represent memory precursors; we demonstrate, with the application of highly active antiretroviral therapy, that the interruption of chronic antigenic stimulation causes significant reductions in the frequency of these cells in five of six patients. In conclusion, this study provides evidence that persistently replicating viral populations are probably required to maintain high frequencies of HIV-1 epitope-specific CD8+ T cells in asymptomatic chronically infected individuals

Download full-text


Available from: Clive M Gray, Dec 29, 2014
  • Source
    • "The HIV-1 protease (PR) plays an essential role in the proper assembly and maturation of HIV virus, including the processing of gag and gag-pol polyprotein precursors [2,3]. The HIV-1 protease has become an important target of anti-HIV therapy, for example, HIV-1 protease inhibitors (PI) are essential components of Highly Active Antiretroviral Therapy (HAART) [4]. The HIV-1 protease is an aspartic protease and its active site is located at the Asp25eThr26eGly27 residues [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The HIV-1 protease has proven to be a crucial component of the HIV replication machinery and a reliable target for anti-HIV drug discovery. In this study, we applied an optimized hierarchical multistage virtual screening method targeting HIV-1 protease. The method sequentially applied SVM (Support Vector Machine), shape similarity, pharmacophore modeling and molecular docking. Using a validation set (270 positives, 155,996 negatives), the multistage virtual screening method showed a high hit rate and high enrichment factor of 80.47% and 465.75, respectively. Furthermore, this approach was applied to screen the National Cancer Institute database (NCI), which contains 260,000 molecules. From the final hit list, 6 molecules were selected for further testing in an in vitro HIV-1 protease inhibitory assay, and 2 molecules (NSC111887 and NSC121217) showed inhibitory potency against HIV-1 protease, with IC50 values of 62 μM and 162 μM, respectively. With further chemical development, these 2 molecules could potentially serve as HIV-1 protease inhibitors. Copyright © 2015 Elsevier Masson SAS. All rights reserved.
    Full-text · Article · Jul 2015 · European Journal of Medicinal Chemistry
  • Source
    • "CD8+ T cell numbers increased during the first two weeks, stabilized by week 4, and then fell, such that circulating CD8+ T cell numbers were not different from baseline after 4 weeks. While circulating CD4+ T cell numbers are characteristically low in HIV+ patients, CD8+ T cell numbers are expanded and in this study remained elevated (compared to numbers in healthy controls) throughout 48 weeks.. Typically, HIV-1 reactivity among circulating CD8+ T cells falls with suppression of HIV-1 replication [32,33]. Are these expanded cells reactive with other microbial pathogens (e.g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The dynamics of CD4+ T cell reconstitution and changes in immune activation and inflammation in HIV-1 disease following initiation of antiretroviral therapy (ART) are incompletely defined and their underlying mechanisms poorly understood. Thirty-nine treatment-naïve patients were treated with raltegravir, tenofovir DF and emtricitabine. Immunologic and inflammatory indices were examined in persons with sustained virologic control during 48 weeks of therapy. Initiation of ART increased CD4+ T cell numbers and decreased activation and cell cycle entry among CD4+ and CD8+ T cell subsets, and attenuated markers of coagulation (D-dimer levels) and inflammation (IL-6 and TNFr1). These indices decayed at different rates and almost all remained elevated above levels measured in HIV-seronegatives through 48 weeks of viral control. Greater first and second phase CD4+ T cell restoration was related to lower T cell activation and cell cycling at baseline, to their decay with treatment, and to baseline levels of selected inflammatory indices, but less so to their changes on therapy. ART initiation results in dynamic changes in viral replication, T cell restoration, and indices of immune activation, inflammation, and coagulation. These findings suggest that determinants of T cell activation/cycling and inflammation/coagulation may have distinguishable impact on immune homeostasis. NCT00660972.
    Full-text · Article · Dec 2013 · PLoS ONE
  • Source
    • "The mechanism behind the inability of CTL to effectively control the viral replication should be explored. Several studies have tried to explain the defects of HIV-specific CD8+ T-cells including phenotypic [6] [7] [8] and functional properties [3] [4] [9] [10] as well as an inability to adequately expand in vitro [9] [11]. It has been demonstrated through previous studies that persons with non progressive infection with superior control over viral replication retain circulating HIV-specific CTLs with higher capacities for cytokine production [12] [13] [14] [15], perforin expression [16] and proliferation [16] [17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Polyfunctional CD8+ T-cells have been described as most competent in controlling viral replication. We studied the impact of antigen persistence on the polyfunctional immune responses of CD8+ T-lymphocytes to HIV Gag and Nef peptides and polyclonal stimuli in 40 ART naïve HIV infected individuals and analyzed the alterations in T-cell functionality in early and late stages of infection. Significantly elevated level of global response and polyfunctional profile of CD8+ T-cells were observed to polyclonal stimulation, than HIV specific antigens in chronically infected individuals. However no key differences were observed in CD8+ T-cell functional profile in any of the 15 unique subsets for Gag and Nef specific antigens. The subjects in early stage of infection (defined as a gap of 6 months or less between seroconversion and enrolment and with no apparent clinical symptoms) had a higher degree of response functionality (4+ or 3+ different functions simultaneously) than in the late stage infection (defined as time duration since seroconversion greater than 6 months). The data suggest that persistence of antigen during chronic infection leads to functional impairment of HIV specific responses.
    Full-text · Article · Feb 2011 · Vaccine
Show more